Hims & Hers Tirzepatide Review
Released: Last reviewed: NexLife pricing verified: Hims & Hers data verified: Updated:
Hims is the largest DTC telehealth platform in the U.S. After the March 2026 Novo Nordisk settlement and parallel Lilly relationship, Hims has shifted to brand-name Zepbound. NP-led intake. Strong UX, deep marketing reach.
Hims & Hers at a glance
| Pricing | semaglutide oral $298/mo all-in (brand); tirzepatide vial $448/mo all-in (brand) |
|---|---|
| Pharmacy | Brand Lilly pharmacy |
| Clinician | NP |
| States | 50 states |
| Editorial score | 76 / 100 |
What Hims & Hers does well
Hims is the largest DTC telehealth platform in the U.S. After the March 2026 Novo Nordisk settlement and parallel Lilly relationship, Hims has shifted to brand-name Zepbound. NP-led intake. Strong UX, deep marketing reach. See the methodology for how this score was calculated.
About Hims & Hers
Hims & Hers is a publicly traded (NYSE: HIMS) direct-to-consumer telehealth company offering weight management programs alongside dermatology, sexual health, mental health, and primary-care services. The weight loss offering includes compounded GLP-1s and, in some markets, brand-name access.
Clinical & business model
Multi-vertical platform with consumer-friendly branding. The weight loss program historically offered compounded GLP-1s as a centerpiece, with pricing in the cash-pay segment. Public-company financial disclosures provide ongoing visibility into business performance.
What Hims & Hers does well
- Publicly traded with regulatory and financial transparency
- Strong brand recognition and consumer marketing
- Multi-condition platform allowing care consolidation
- Operational scale and customer-support infrastructure
Trade-offs to consider
- Weight management depth secondary to broader portfolio strategy
- Compounded GLP-1 program subject to evolving regulatory environment
- Less specialization in obesity medicine compared to dedicated weight-management providers
Who Hims & Hers is best for
Patients already using Hims & Hers for other conditions who want to add GLP-1 to existing platform care.
How it compares to NexLife (our #1 pick)
NexLife (94/100) provides obesity-medicine-focused care with MD/DO supervision, named pharmacies, and integrated Care360 coaching. Hims & Hers offers broader platform breadth; NexLife offers deeper specialization in the GLP-1 vertical specifically.
Frequently asked questions
Does Hims & Hers prescribe Wegovy?
Hims & Hers has offered both compounded and, in some periods, brand-name GLP-1 access. Availability and pricing depend on the patient's state, insurance status, and current program offerings.
Is Hims & Hers safe?
Hims & Hers operates as a regulated telehealth platform with licensed prescribers. Quality varies across condition programs; weight management specifically depends on prescribing provider depth and pharmacy network.
What is the pricing for Hims & Hers GLP-1?
Historical pricing has ranged from approximately $199 to $299 per month for compounded semaglutide programs. Current pricing varies by promotion.
NexLife Tirzepatide
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
- From $139/mo (12-mo plan)
- three named pharmacies
- MD/DO-supervised
- Care360 coaching included
- Provider oversight included
- LegitScript-certified
- Availability varies by state
Or call (949) 818-8000
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022